Fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) signaling plays essential roles in bone development and diseases. Missense mutations in FGFs and FGFRs in humans can cause various congenital bone diseases, including chondrodysplasia syndromes, craniosynostosis syndromes and syndromes with dysregulated phosphate metabolism. FGF/FGFR signaling is also an important pathway involved in the maintenance of adult bone homeostasis. Multiple kinds of mouse models, mimicking human skeleton diseases caused by missense mutations in FGFs and FGFRs, have been established by knock-in/out and transgenic technologies. These genetically modified mice provide good models for studying the role of FGF/FGFR signaling in skeleton development and homeostasis. In this review, we summarize the mouse models of FGF signaling-related skeleton diseases and recent progresses regarding the molecular mechanisms, underlying the role of FGFs/FGFRs in the regulation of bone development and homeostasis. This review also provides a perspective view on future works to explore the roles of FGF signaling in skeletal development and homeostasis.
INTRODUCTION
Skeletons are formed through two distinct developmental modes, namely intramembranous ossification and endochondral ossification. The former is directly accomplished by osteoblast differentiation from mesenchymal cells; the latter involves initial differentiation of mesenchymal cells into chondrocytes to form a cartilage template and subsequent replacement by bone. 1 The cranium and medial clavicles are formed through intramembranous ossification. Long bones, including the appendicular skeleton, facial bones and vertebrae, are formed through endochondral ossification. [2] [3] Various signaling molecules control the process of skeleton development, such as fibroblast growth factor (FGF), wingless-type MMTV integration site family members (Wnt) and bone morphogenetic protein (BMP) signaling pathways. Among these signaling pathways, FGF/fibroblast growth factor receptor (FGFR) signaling is very essential. The activated FGFRs recruits target proteins to its cytoplasmic tail and modifies these proteins by phosphorylation, 6 leading to the activation of intracellular downstream signaling pathways, such as mitogen-activated protein kinase (Ras/MAPK), phosphoinositide 3-kinase/Akt (also known as protein kinase B), phospholipase C and protein kinase C pathways. Furthermore, FGF signaling can also stimulate the signal transducers and activators of transcription (STAT) 1/p21 pathway 2,7 ( Figure 1 ). Multiple kinds of mouse models with genetic modifications of FGF/FGFR have been generated. In our review, we summarize the use of these mouse models in the research of the role of FGF/FGFR signaling in skeleton development and homeostasis.
prehypertrophic and hypertrophic chondrocytes.
9, [11] [12] FGFR1 is also expressed in osteoblasts and osteocytes (Table 1) . [13] [14] [15] [16] A series of mouse models of Fgfr1 have been generated to genetically dissect the functions of Fgfr1 during gastrulation and later developmental processes. Fgfr1-deficient (Fgfr1 2/2 ) embryos display severe growth retardation, and died prior to or during gastrulation because of intrinsic blocks in mesodermal differentiation. [17] [18] Deletion of the Ig domain IIIc of Fgfr1 (Fgfr1IIIc) leads to gastrulation defects resembling the Fgfr1 2/2 alleles. However, mice with Fgfr1IIIb ablation are viable and fertile, suggesting that IIIc is the dominant isoform for the majority of FGFR1 functions in embryogenesis. 19 Chimeras were generated by injecting Fgfr1 2/2 embryonic stem cells into wild-type blastocysts to circumvent the gastrulation defect. The milder mutant chimeras exhibit deformed limb buds and varying degrees of reduction in limb skeletal elements. [19] [20] [21] Mice with targeted deletion of FGFR1 in all limb bud mesenchymal cells (via T (brachyury)-cre), 22 or posterior limb bud mesenchyme (via Shh-cre) 23 were used to further study the role of FGFR1 in limb development. T-cre; Fgfr1 mice die at birth and show reduced limb skeleton, misshapen forelimb/hindlimb bud and missing digits, whereas Shh-cre Fgfr1 mice display normal limb bud size, but missed a digit. 10 Li et al. 24 assessed the roles of FGFR1 signaling in forelimb and hindlimb development by disrupting this gene, using AP2-Cre and Hoxb6-Cre transgenic mice that express Cre recombinase in complementary temporal and spatial patterns during limb bud formation.
The results indicate that disruption of Fgfr1 at an earlier stage, prior to thickening of limb mesenchyme, results in Mouse models for FGF/FGFR signaling in skeleton research N Su et al 2 more severe defects, characterized by malformation of the apical ectodermal ridge (AER).
FGF receptor-specific substrates (Frs) act as the principal mediators for FGFR1 signal transduction. Mice that lack the Frs-binding site on FGFR1 (Fgfr1 DFrs/DFrs ) die during late embryogenesis, and exhibit defects in neural tube closure, and in the development of the tail bud and pharyngeal arches. However, mutant FGFR1 still has functions during gastrulation and somitogenesis, indicating that distinct signal transduction mechanisms of FGFR1 signaling in different developmental contexts. 25 Osteoglophonic dysplasia (OD) patients, resulting from activating mutations of FGFR1, exhibit rhizomelic dwarfism, 26 indicating that FGFR1 is a negative regulator of long bone growth. Embryos with conditional deletion of Fgfr1 in osteochondro-progenitor cell lineages show increased height of the hypertrophic zone due to delayed degradation, or maturation of hypertrophic chondrocytes, or decreased osteoclastogenesis. 15 Studies in humans and mice also reveal that FGFR1 play crucial role in bone formation. A gain-of-function mutation in FGFR1 (P252R) leads to Pfeiffer syndrome (PS), one type of craniosynostoses, characterized by premature fusion of one or several calvarial sutures. 27 Several activating mutations of FGFR1 in OD patients also lead to craniosynostosis in addition to rhizomelic dwarfism. 26 Mice carrying a P250R mutation in FGFR1 were generated to mimic human PS. Studies using these mutant mice uncovered that FGFs/ FGFR1 signals may regulate intramembranous bone formation. 28 Jacob et al. 15 found that adult mice, with deletion of Fgfr1, exhibited increased bone mass. Deletion of Fgfr1, in osteochondro-progenitor cells in mice (via Col2-cre), leads to increased proliferation and delayed differentiation, and matrix mineralization of osteoblasts, while inactivation of Fgfr1 in differentiated osteoblasts (via Col1-cre) causes accelerated osteoblast mineralization differentiation. 15 It has been proposed that FGFR1 promotes the differentiation of mesenchymal progenitors into preosteoblasts, but inhibits the proliferation of mesenchymal progenitor cells, as well as the maturation and mineralization of osteoblasts. 15 Impaired osteoclast activity is another reason for increased bone mass in mice with Fgfr1-deficient in differentiated osteoblasts. To explore the direct effect of FGFR1 on osteoclasts, Lu et al. 29 generated mice with targeted deletion of Fgfr1 in bone marrow monocytes and osteoclasts using LysM-cre. The mutant mice exhibit increased bone mass, impaired osteoclast formation and activity indicating the positive regulation of FGFR1 on osteoclasts. The role of FGFR1 in osteocytes is still not Mouse models for FGF/FGFR signaling in skeleton research N Su et al 3 clarified and should be studied by deletion of Fgfr1 in osteocytes using dentin matrix protein-1(Dmp1)-Cre ( Figure 2 ). In addition to the effect of FGFR1 on limb development and bone formation or remodeling, FGFR1 also participates in phosphorus metabolism. Osteoglophonic dysplasia patients have non-ossifying bone lesions, hypophosphatemia and increased serum level of FGF23, a member of the FGF family, which is a circulating phosphaturic hormone produced mainly by osteoblasts and osteocytes. [30] [31] Pharmacological inhibition of FGFR1 inhibits FGF23 transcription in bone of animal models. 32 40, 47 Among them, AS is one of the most severe craniosynostoses. S252W and P253R mutations in FGFR2 are responsible for nearly all known cases of AS.
2,47
Several gain-of-function mutant mouse models, mimicking human craniosynostoses, have been generated to study the mechanism of FGFR2 for regulating the suture development. ) (equivalent to mutation in human causes CS/PS), premature fusion of 54 This finding may reflect the differences in the timing of Fgfr2 inactivation. 36 These differences can be further explored by conditional deletion of FGFR2 in osteoblastic cells. Fgfr2IIIc -/-mice also exhibit dwarfisms, reduced growth of the skull base and axial, as well as appendicular skeletons, which is associated with decreased proliferating chondrocytes and hypertrophic zone in these endochondral bones. This leads to premature loss of skull base sutures and smaller-than-normal long bones and vertebrae. 54 The expressions of chondrocyte markers Ihh and PTH-related peptide (PTHrP) are also diminished in Fgfr2IIIc -/-mice. 54 These results suggest that Fgfr2IIIc regulates chondrocyte lineages. Fgfr2; Dermol-Cre mice have decreased bone length without apparent defects in chondrocyte proliferation, but show shortened hypertrophic zone, which is similar to that in Fgfr2IIIc -/-mice. 54 Increased osteoclast activity may account for decreased hypertrophic zone by increasing the removal of calcified hypertrophic chondrocyte matrix. 36 Genetic mouse models are also used to find therapeutic strategy. Activated ERK1/2 and p38 signaling pathways may participate in the regulation of coronal suture by FGFR2. 39, 49, 52 The premature fusion of cranial sutures can be partially rescued by blocking ERK1/2 or p38 activation, respectively in vitro and in vivo. 39,49,52,56 Shukla et al. [56] [57] showed that RNA interference targeting the mutant form of FGFR2 S252W completely rescued Apert-like syndrome in mice, and local treatment of the Apert mice with U0126, an inhibitor of MEK1/2, significantly alleviated craniosynostosis. Using genetically modified mice simultaneously carrying C342Y, L424A and R424A mutations in the same FGFR2c (Fgfr2cCLR), researchers found that the activated FGFR2 signaling caused by C342Y mutation, cannot recruit and stimulate tyrosine phosphorylation of FRS2. 53 Thus, premature fusion of sutures, mediated by activated FGFR2IIIc, is prevented by attenuation of the signaling pathways through selective uncoupling between the docking protein FRS2a and activated FGFR2IIIc. 53 These studies provide opportunities for developing novel therapeutic strategies for craniosynostoses.
FGFR3
FGFR3 is first expressed in chondrocytes, differentiated initially from the core of the mesenchyme condensation.
58
FGFR3 is expressed in reserve and proliferating chondrocytes as the epiphyseal growth plate is formed.
12,58-59
Immunohistochemistry results have indicated that FGFR3 is also expressed in mature osteoblasts and in osteocytes.
14 During calvarial bone development FGFR3 is expressed at low levels in sutural osteogenic fronts at the late stages (Table 1) . 34, 38 Gain-of-function point mutations in FGFR3 cause several types of the human skeletal dysplasias, including achondroplasia (ACH), hypochondroplasia (HCH), thanatophoric dysplasia (TD) and severe achondroplasia, with developmental delay and acanthosis nigricans (SADDAN). 60 Among these diseases, ACH is the most common type of human dwarfism characterized by short stature, especially in the proximal upper and lower limbs, central facial dysplasia, macrocephaly and spine protrusion. [61] [62] [63] The phenotype of HCH is similar to ACH, but much milder than ACH, whereas TD is the most common form of lethal skeletal dysplasia characterized by macrocephaly, narrow bell-shaped thorax, severe shortening of the limbs and lethality in the neonatal period. TD has been classified into TDI and TDII. TDI patients have curved, short femurs, with or without cloverleaf skull, and TDII patients have relatively longer femurs with severe cloverleaf skull. 64 Patients with SADDAN exhibit acanthosis nigricans and anomalies in the central nervous system, in addition to severe skeletal dysplasia. [65] [66] Currently, multiple FGFR3-related mouse models have been generated using genetic approach to study the role of FGFR3 in skeleton development and diseases. Mice carrying activating mutations of FGFR3 mimicking human ACH exhibit smaller body size, dome-shaped skull and shortened long bones with disorganized chondrocyte columns in growth plates. 60, [67] [68] [69] [70] Mice carrying FGFR3 K644E mutation mimicking human TDII die within few hours after birth, whereas mice carrying FGFR3 S365C mutation, which corresponds to FGFR3 S371C mutation in human
Mouse models for FGF/FGFR signaling in skeleton research N Su et al 5 TDI, exhibit skeletal dysplasia more severe than ACH. [71] [72] FGFR3 negatively regulates chondrogenesis of long bones by affecting the proliferative activity and differentiation of chondrocytes. A number of reports have demonstrated that FGFR3 signaling inhibits chondrocyte proliferation through STAT1 signaling by inducing the expression of cell cycle suppressor genes such as the CDK inhibitor p21. [73] [74] [75] [76] Loss of Stat1 restored the reduced chondrocyte proliferation in ACH mice, but did not rescue the reduced hypertrophic zone or the delayed formation of secondary ossification centers in ACH mice. The expression of a constitutively active mutant of MEK1 in chondrocytes of Fgfr3-deficient mice inhibits skeletal overgrowth, strongly suggesting that FGFR3 inhibits chondrocyte differentiation through the ERK/MAPK pathway. 76 In contrast, evidence suggests that FGFR3 promote chondrocyte terminal hypertrophic differentiation. [77] [78] Conversely, mice carrying targeted deletion of FGFR3 exhibit overgrowth of long bone, wider hypertrophic zone, proliferative zone and enhanced proliferative activity of chondrocytes. 59, 79 Moreover, the activity and the signaling outcomes of the FGFR3 pathway during chondrogenesis are also influenced by many intracellular and extracellular signals. Activated FGFR3 inhibits BMP4 expression in post-natal mouse growth plates, 80 while BMP treatment rescues the retarded growth of long bone in ACH mouse model.
77
These studies emphasize the antagonistic interaction between FGFR3 and BMP signaling in the control of chondrogenesis. Moreover, IHH expression is reduced in mice carrying activating FGFR3. 80 PTHrP partially reverses the inhibition of long bone growth caused by FGFR3 activation. 72 It was suspected that FGFR3 signaling may act upstream of the IHH/PTHrP system in regulating the onset of hypertrophic differentiation. 77 In addition, it was reported that IGF1 prevents the apoptosis, induced by FGFR3 mutation, through the phosphoinositide 3-kinase pathway and MAPK pathways.
81
FGFR3 signaling is also an important regulator of osteogenesis. Chondrocyte-specific activation of FGFR3 in mice causes premature synchondrosis closure and enhanced osteoblast differentiation around synchondroses. Premature synchondrosis closure is also observed in the spine and cranial base in human cases of homozygous ACH and TD, as well as in mouse models of ACH, with increased bone formation. 70, 72, 82 Activated FGFR3 leads to decreased bone mass by regulating both osteoblast and osteoclast activities. [83] [84] Mice lacking FGFR3 also have decreased bone mineral density and osteopenia. 14,85 FGFR3 can inhibit proliferation of BMSCs in vitro. 83, 85 However, both deletion and activation of FGFR3 can lead to increased differentiation, but impaired mineralization of osteoblasts ( Figure 2 ). 83, 85 The reasons for these seemingly inconsistent results need to be explored.
Given its causal role in some skeletal disorders, including ACH, FGFR3 and/or its downstream pathways, are attractive targets for therapy. C-type natriuretic peptide is a newly identified potential therapeutic antagonist of FGFR3 signaling that alleviates the dwarfism phenotype of mice mimicking human ACH through its inhibition on FGFR3/MAPK pathway. [86] [87] It was reported that parathyroid hormone (PTH) stimulates the longitudinal bone growth in rats and improves the growth of the cultured femurs from mice carrying a gain-of-function mutation (G380R) of FGFR3. [88] [89] In addition, we have found previously that PTHrP partially reversed the shortening of cultured bone rudiments from ACH mice. 72 Recently, we found that systemic intermittent injection of PTH can rescue the lethal phenotype of TDII mice and significantly alleviate the retarded skeleton development of ACH mice. 90 We also have identified a novel inhibitory peptide for FGFR3 signaling, which alleviated the bone growth retardation in bone rudiments from mice mimicking human TDII and reversed the neonatal lethality of TDII mice.
91

FGFR4
In addition to its expression in the resting and proliferative zones of growth plates, 11 FGFR4 is also highly expressed in rudimentary membranous bone and strictly localized in osteoblasts between the periosteal and endosteal layers (Table 1) . 92 Interestingly, Fgfr4-deficient mice are developmentally normal, but the Fgfr3/Fgfr4 double null mice grow more slowly. 93 However, the effect of FGFR4 on bone development remains unclear and needs further studies. These mice display failed limb development with substantial reduction in limb-bud size, and hypoplasia or aplasia of specific skeletal elements. 112 However, the Msx2 promoter drived cre is not expressed sufficiently early to completely ablate Fgf8 function during forelimb formation, which results in a complex forelimb phenotype. Using Rarb-Cre mice, Fgf8 is conditionally deleted in the developing forelimb AER. These mice have severe forelimb deformity, including the absence of radius and first digit. [125] [126] In addition to its important role in limb development, FGF8 also regulates osteoblast and chondrocyte differentiation. FGF8 is expressed in chondrocytes and perichondrium of dorsal costal bone, as well as in the osteoblast compartment of calvarial bone in cortical bone and the growth plate of developing bones. 60, 127 FGF8 can effectively predetermine mouse BMSCs and C2C12 cell line to differentiate to osteoblasts and increase bone formation in vitro.
FGFS PARTICIPATE IN SKELETON DEVELOPMENT AND BONE METABOLISM
128-129 However, Lin et al. 130 found
Mouse models for FGF/FGFR signaling in skeleton research N Su et al 7 that FGF8 stimulated the proliferation of MC3T3E1 or primary rat osteogenic cells, but inhibited osteogenic differentiation and mineralization. These controversial results may be attributed to the different cells used in in vitro experiments. As to cartilage, FGF8 can promote the degradation of cartilage and exacerbation of osteoarthritis. 131 However, the influence of FGF8 on bone and cartilage remains unclear.
FGF9
FGF9 has the highest affinity to FGFR3, and can also bind FGFR2 with a lower affinity ( 138 Furthermore, the loss of Fgf9 results in a deficiency of osteoclasts in the perichondrium and primary spongiosa of developing bone. 135 These findings suggest that FGF9 can positively regulate osteogenesis and osteoclastogenesis in endochondral ossification. FGF9 is also expressed in the mesenchyme of suture in the early craniofacial development stages. 115 By contrast to its promoting effects on osteogenesis in endochondral ossification, targeted overexpression of FGF9 in cranial mesenchymal cells leads to a switch from intramembranous to endochondral ossification in mouse parietal bones, indicating that FGF9 may regulate bone development by affecting the direction of mesenchyme differentiation. 139 Recently, missense mutations in FGF9 have been identified to result in elbow-knee synostosis, premature fusion of cranial sutures in mice 140 and multiple synostosis syndrome in humans. 141 These data further suggest the important effect of FGF9 on bone development. However, the different impacts of FGF9 on different stages of limb development and the direct effect of FGF9 on adult bone homeostasis are still unclear. Targeted deletion of Fgf9 in different stages and cells using Fgf9 CKO mice 142 are necessary to answer these questions in the future.
FGF10
FGF10 is expressed in the lateral plate mesoderm and serves as a mesenchymally expressed limb bud initiator, 44, [143] [144] and the expression persists in the mesenchyme under AER after initial limb bud formation. FGF10 acts epistatically at the upstream of FGF8. 145 Positive feedback exists between FGF8 and FGF10, which is essential for limb development. 44 To define the role of FGF10, Fgf10 knockout (Fgf10 2/2 ) mouse strain was generated. These mice show complete absence of fore-and hindlimbs, and die after birth associated with complete absence of lungs. [145] [146] The limb bud formation in Fgf10 2/2 embryos is initiated but outgrowth of the limb buds is impaired, while the clavicle formation is normal. 146 However, the impact of FGF10 on postnatal bone development and modeling remains unclear.
FGF18
FGF18 is expressed in osteogenic mesenchymal cells and differentiating osteoblasts of developing calvaria, in the perichondrium and joints, as well as growth plates of developing long bones.
11,147-148
Fgf18 knockout (Fgf18 2/2 ) mice die shortly after birth, and display expanded zones of proliferating and hypertrophic chondrocytes with increased chondrocyte proliferation and differentiation, similar to that observed in mice lacking Fgfr3. 150 supporting the promoting effect of FGF18 on osteogenesis. These data indicate that FGF18 may be an important modulator for both endochondral and intramembranous bone formation in adult mice. Although FGF18 is a key regulator for chondrogenesis, osteogenesis and vascularization of early skeleton development, the mechanism and the direct effect of FGF18 on the three critical stages in skeleton developmental or bone homeostasis at adult period need to be further studied.
FGF21
FGF21 is a member of the FGF19/21/23 subfamily that functions as an endocrine hormone. [153] [154] FGF21 is a powerful regulator of glucose and lipid metabolism. [155] [156] [157] [158] Recently, FGF21 has also been found to participate in bone homeostasis. The overexpression of Fgf21 in liver driven by Apoe promoter in transgenic mice show decreased bone mass, impaired bone formation and increased osteoclast function, which is consistent with the phenotypes of mice with pharmacological FGF21 treatment. In contrast, Fgf21 2/2 mice have increased bone mass with improved osteogenesis and decreased osteoclast function. The possible mechanism is that FGF21 stimulates adipogenesis from bone marrow mesenchymal stem cells by potentiating the activity of peroxisome proliferator-activated receptor c, but inhibits osteoblastogenesis. 159 These results indicate that FGF21 is a negative regulator of bone turnover and a key integrator of bone and energy metabolism, and underscores the importance of the whole body energy metabolism in bone physiology. 159 Furthermore, FGF21 is expressed in the growth plate, [160] [161] and is associated with reduced skeletal growth and growth hormone (GH) insensitivity caused by undernutrition. After food restriction, FGF21 expression is increased in the tibial growth plates of mice. Fgf21 renal NaPi-2a in the brush border membrane of proximal tubules. 182 The renal phosphate wasting in the transgenic mice is accompanied by the reduced expression of NaPi2a. 179 The reduction of serum 1,25(OH) 2 D levels may result
Mouse models for FGF/FGFR signaling in skeleton research N Su et al 9 from a significant decrease in renal mRNA level for 25-hydroxyvitamin D-1a-hydroxylase (1a-OHase) and a simultaneous elevation of 24-hydroxylase mRNA, induced by increased serum level of FGF23 (Figure 3 ). Recent studies have indicated the regulation of iron on FGF23. Reduced serum iron concentrations are strongly correlated with increased serum FGF23 in ADHR patients, 186 and C-terminal FGF23 is negatively correlated with ferritin. 187 To investigate the effect of iron on the development of the ADHR phenotype, R176Q-Fgf23 knock-in mice mimicking human ADHR are generated and placed on control or low-iron diets.
188-189 R176Q-
Fgf23 knock-in mice on low-iron diet have elevated intact C-terminal Fgf23 with hypophosphatemic osteomalacia and low serum 1,25(OH) 2 D. Iron chelation in vitro results in a significantly increased Fgf23 mRNA level that depends on MAPK signaling. 189 However, the mechanism for the regulation of FGF23 by iron is still unclear. Increased FGF23 level is also found in patients with hypophosphatemic diseases including XLH and autosomal dominant hypophosphatemic rickets (ARHR). XLH is caused by inactivating mutations in phosphate regulating gene with homologies to endopeptidases on the X chromosome (PHEX). [190] [191] Mice with ablation of Phex gene (Hyp mice) have increased FGF23 expression and hypophosphatemia. 192 Both the serum phosphate levels and skeletal changes in Hyp mice can be reversed by introducing Fgf23 null mutation into Hyp mice, 166, [193] [194] indicating that enhanced FGF23 level is responsible for the hypophosphatemia in XLH patients and Hyp mice. The increased FGF23 level is due to the improved Fgf23 expression, but not decreased degradation. 165, [194] [195] ARHR results from missense mutations in DMP-1. Dmp1 knockout mice exhibit hypophosphatemic rickets and osteomalacia similar to ARHR patients. [196] [197] Both Dmp1 null mice and patients with ARHR show elevated serum FGF23 levels. Considering the role of FGF23 in ADHR and other hypophosphatemic diseases, ARHR has been proposed to be associated with excessive actions of FGF23. FGF23 also participates in some clinical pathological processes, in addition to its role in genetic diseases. In patients with chronic kidney disease (CKD), FGF23 level is elevated due to increased serum calcium and phosphate concentrations and PTH, 31, 198 and is associated with increased FGF23 transcription in bone. 199 Some researchers proposed that FGF23 might be an early biomarker for earlier interventions in CKD. 200 However, the reason for the high serum levels of FGF23 in CKD is unclear. Furthermore, elevated level of FGF23 in CKD patients have been linked to greater risks of left ventricular hypertrophy (LVH). [201] [202] Using animal models, Faul et al. 203 found that increased level of FGF23 in mice resulted in pathological hypertrophy of cardiomyocytes and LVH. To avoid redundancy and PTH Mouse models for FGF/FGFR signaling in skeleton research N Su et al 10 Table 2 Mouse models with genetically modified FGF/FGFR signaling in skeletal development and homeostasis Mouse models for FGF/FGFR signaling in skeleton research N Su et al 11 Table 2 . Mouse models for FGF/FGFR signaling in skeleton research N Su et al 13 Mouse models for FGF/FGFR signaling in skeleton research N Su et al 16
give full attention of the exciting results from FGF23 studies, we encourage you to read the recently published review by Quarles and Bhattacharyya. 31, 204 
OTHER FGFS
In addition to the FGFs mentioned above, the roles of majority of these 22 FGFs are not defined in skeleton development and homeostasis. Researchers have generated knockout or CKO mouse models of these FGFs (Table 2 ). Fgf3 knockout mice show a short, dorsally curled tail, caudal vertebrae and smaller body. 205 Some mouse models show normal skeleton phenotypes, such as mice lacking FGF1, FGF5, FGF6, FGF7, FGF17 or FGF22. [206] [207] [208] [209] [210] [211] [212] The skeleton phenotypes of knockout mice lacking FGF11-FGF16, or FGF20, are still not analyzed. [213] [214] [215] [216] [217] [218] [219] The effect of these FGFs on bone development or homeostasis need be further studied.
CONCLUSIONS
Studies in human patients and mouse models with FGFs/ FGFRs mutations have shown important roles of FGF signaling in skeletal development, genetic skeletal diseases and bone homeostasis. So, FGF/FGFR signalings will be attractive targets for treating bone related diseases. FGF/FGFR signals control the balance among skeletal cell growth, differentiation and apoptosis during development and adult homeostasis, as well as regulate systemic phosphate homeostasis. However, many unresolved issues still need to be explored. Many studies have investigated the role of FGFRs in endochondral and intramembranous bone formation during development, but the effects of FGFRs on osteoclasts, especially on osteocytes, have not be clarified. Osteocytes are the most abundant and longest-living cells in the adult skeleton and have essential roles in bone homeostasis. [220] [221] Thus, uncovering the impact of FGFRs on osteocytes using osteocyte-specific Cre mice is critical. Compensation, or crosstalk, may occur between different FGFRs during skeleton development. For example, conditional knock out of Fgfr1 in mature osteoblasts leads to increased FGFR3 expression, 15 whereas both cultured bone marrow stromal cells from Fgfr3 null mice, or mice carrying gain-of-function mutation in FGFR3, have increased expression of FGFR1. 83, 85 Crossing between mouse strains harboring various FGFRs mutations is extremely important to elucidate the interactions between different FGFRs. So far, only part of the 22 known FGF ligands have been shown to be essential for skeletal development, such as FGF8, FGF9 and FGF10. However, the mechanisms remain unclear because most of the knockout mice die before or after birth. Conditional deletion of these FGFs using bone cell-specific Cre mice is necessary to study their roles during bone development. The function of other unexplored FGFs in skeletogenesis remains to be discovered. Furthermore, which FGFRs are the relatively specific receptors of these unexplored FGFs during bone development and metabolism are unknown. Crossing mouse strains harboring different FGFs mutations with FGFRs mutant mouse models is necessary to discover the interactions between FGFs and FGFRs in skeleton development and homeostasis.
Recently, studies have indicated that the bone is closely related with whole-organism physiology. 222 For example, bone can regulate energy metabolism, male reproduction and hematopoiesis. [223] [224] Some hormone secreted from other organs or tissues also have effect on bone, such as Leptin secreted by adipocyte. 222 In addition, systemic disease also influence skeleton such as CDK 225 and inflammatory disease. [226] [227] The roles of FGF signaling in the effect of systemic diseases on bone or bone on whole-organism physiology remain unclear and need further exploration.
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